Breast Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Growing prevalence of breast cancer

An expanding at-risk female population sustains demand for advanced imaging. The American Cancer Society predicts 310,720 new invasive cases and 42,250 deaths in the United States during 2024, reinforcing the value of early detection.^{[1]American Cancer Society, “Cancer Facts & Figures 2024,” cancer.org} Incidence climbs fastest in Eastern Europe, while rising obesity and later first-birth age widen the screening cohort across emerging economies. Ageing demographics amplify volumes because risk escalates steeply after menopause, driving planners to enlarge capacity and upgrade to higher-sensitivity tools. Regular screening improves five-year survival, and payers increasingly treat it as a cost-saving measure rather than a discretionary expense.

Rapid uptake of 3-D/DBT mammography

Digital breast tomosynthesis reduces tissue-overlap artefacts and lowers false-positive callbacks by up to 15% Updated EU guidelines recommend DBT for routine screening, prompting wholesale replacement of 2-D units in public fleets. Providers in the United States still upgrade despite Medicare fee cuts because DBT attracts patient preference and mitigates medicolegal risk. When paired with triage algorithms, DBT shortens interpretation time and lifts throughput, enabling centres to balance lower unit reimbursement with higher daily exam counts.

AI-powered image analysis boosts workflow efficiency

Radiologist shortages leave more than 1,400 breast-imaging posts vacant in the United States in 2025. Cloud-delivered algorithms now mark suspicious regions, stratify risk, and auto-populate structured reports. RadNet’s USD 48 million purchase of iCAD in 2024 highlights the competitive value of owning differentiated AI pipelines.^{[2]RadNet Inc., “RadNet Completes Acquisition of iCAD,” radnet.com} EU Artificial Intelligence Act rules lengthen certification cycles, yet uniform regulation promises pan-European scale once clearance is achieved. Facilities adopt subscription models to access continual software improvements without fresh capital outlay.

Portable handheld ultrasound broadens access

Handheld probes priced far below cart-based systems reach community clinics, mobile vans, and primary-care offices where fixed rooms are scarce. During the COVID-19 emergency these devices preserved screening continuity while limiting hospital visits. Cloud upload lets city specialists read exams captured in rural settings, closing equity gaps and sustaining breast imaging market growth in low-resource geographies. Image resolution still trails premium ultrasound, restricting use in complex diagnostic work-ups, but manufacturers improve probe bandwidth and AI-driven noise reduction with each generation.

High upfront cost of DBT systems

Full-featured scanners list between USD 400,000 and USD 600,000, stretching capital budgets for independent sites. Consecutive Medicare fee cuts of 11.72% in 2024 and 9.67% in 2025 erode payback calculations. Vendors counter with trade-in credits and usage-based financing, yet adoption lags in price-sensitive regions, slowing replacements of ageing 2-D fleets.

Shortage of sub-specialty radiologists

Graduate caps restrict training slots, and retirements outpace new entrants, lengthening reading queues in rural and middle-income markets. Tele-interpretation and AI relieve volume spikes, but complex cases still demand board-certified expertise. Workforce gaps therefore limit the full utilisation of installed imaging capacity.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Breast Imaging Market Segment Analysis

Mammography produced 38.12% of 2025 revenue, anchoring the breast imaging market even as DBT reshapes modality mix. The 3-D upgrade path supports a 12.38% CAGR to 2031, validated by European Commission screening guidance that highlights superior invasive-cancer detection. Breast ultrasound persists as the leading adjunct, providing radiation-free evaluation in dense tissue and in high-risk cohorts. Magnetic resonance imaging (MRI) retains gold-standard status for hereditary risk populations but faces cost and contrast-agent barriers.

Image-guided biopsy workflows integrate seamlessly with diagnostic imaging, streamlining tissue sampling under mammographic, ultrasound, or MRI guidance. Vacuum-assisted systems improve diagnostic yield and patient comfort, while clip-placement advances aid surgical localization. Molecular breast imaging (MBI) remains a targeted problem-solver when other modalities deliver inconclusive results, though radiation exposure limits broad use. AI overlays on each technique raise diagnostic consistency and cut observer variability, further embedding algorithmic support in daily practice.

Ionizing platforms still account for 61.74% of global sales, reaffirming their ubiquity in national screening programs. Yet non-ionizing modalities post a 10.29% CAGR through 2031 as payer and patient sentiment shifts toward radiation-free solutions. Automated breast ultrasound (ABUS) and contrast-enhanced ultrasound expand beyond handheld scans, addressing reproducibility and sensitivity concerns. High-field MRI systems push anatomic detail higher, while abbreviated protocols shorten table time and cost.

Artificial intelligence reduces exposure in ionizing studies by optimizing acquisition parameters, and hybrid workstations suggest second-look ultrasound for suspicious mammograms, blending both technology classes. Capital costs still tilt higher for MRI, but lifecycle savings accrue from reduced regulatory compliance on radiation. Over the forecast horizon, market competition will likely hinge on delivering diagnostic power with minimal or no ionizing dose.

Screening programs generated 53.16% of 2025 revenue, proving that early detection anchors the breast imaging market size. However, interventional or therapeutic imaging rides a 10.21% CAGR, propelled by advances in MRI-guided focused ultrasound, stereotactic radiosurgery planning, and real-time navigation during minimally invasive procedures. Diagnostic imaging sits squarely in the middle, translating screening recalls into actionable lesion characterization through contrast, diffusion, or elastography sequences.

Clinicians increasingly monitor therapy with imaging biomarkers, adjusting regimens mid-course to spare toxicity and boost outcomes. Post-procedure surveillance also relies on high-resolution modalities to spot recurrences early. As workflow ties tighten between detection and treatment, vendors position integrated platforms that cover the continuum rather than sell stand-alone scanners.

Hospitals retained 61.95% revenue share in 2025, yet diagnostic imaging centers outpace all others with an 11.28% CAGR. Payers favor these outpatient venues for lower facility fees, and patients appreciate faster scheduling. The RadNet–iCAD deal reflects how algorithmic speed gains translate directly into center profitability through higher daily throughput. Ambulatory surgery centers invest in advanced guidance systems so surgeons can biopsy or ablate tumors without hospital admission, broadening addressable procedure volumes.

Academic hospitals nevertheless hold the edge in complex cases requiring multidisciplinary input, threading imaging, pathology, and oncology under one roof. They also act as early adopters of cutting-edge research protocols, setting the stage for downstream community uptake. Tele-radiology partnerships now let suburban sites tap city-center expertise, blurring the lines between care settings and allowing the breast imaging market to follow patients outside traditional walls.

Geography Analysis

North America Breast Imaging Market

North America produced 35.98% of 2025 revenue. The breast imaging market benefits from federally mandated dense-breast notifications effective September 2024, which lift demand for supplemental ultrasound and MRI. AI adoption matures fastest here because early algorithm clearances and venture funding support broad deployment. Growth moderates, however, because replacement purchases dominate a saturated installed base.

Europe Breast Imaging Market

Europe follows with high screening penetration and unified clinical guidelines that now recommend DBT. The European Artificial Intelligence Act sets a harmonised approval path, lengthening validation but ultimately creating a single digital market. Public health agencies co-finance refresh cycles, and competitive tenders encourage volume-based discounts that widen access to mid-sized clinics.

APAC Breast Imaging Market

Asia-Pacific shows the strongest 10.61% CAGR. Government insurance schemes in China fund biennial mammograms for millions of women, while India’s Ayushman Bharat drives mobile vans into secondary cities. Middle-class awareness campaigns and international NGO partnerships further widen screening coverage. Capital spending migrates from tier-one metros to provincial hubs, where handheld ultrasound and entry-level MRI enable affordable services. Regulatory heterogeneity persists, but local manufacturing incentives attract global vendors into joint ventures.

MEA and South America Breast Imaging Market

The Middle East & Africa and South America trail in revenue but post steady single-digit growth. Oil-exporting Gulf states buy premium suites for public centres, whereas sub-Saharan Africa relies on mobile vans and donor funding. Brazil expands public screening capacity, but reimbursement lags, restraining wholesale adoption of DBT.

Regulatory Landscape

In the United States, breast imaging providers and OEMs operate under the Mammography Quality Standards Act (MQSA), including the FDA final rule that made dense-breast notification requirements effective September 10, 2024. The MQSA framework links equipment performance, facility certification, and quality assurance to continued participation in screening programs, which shapes upgrade cycles toward compliant digital mammography and DBT systems.

For software-led innovation, the FDA added a clearer pathway for certain AI imaging functions by classifying radiological machine learning-based quantitative imaging software with a predetermined change control plan as Class II (special controls) under 21 CFR 892.2055, effective June 17, 2026. In Europe, the EU Medical Device Regulation (Regulation (EU) 2017/745, consolidated text applicable from January 1, 2026) remains the core compliance framework for high-risk devices, while Regulation (EU) 2024/1860 (adopted June 13, 2024) supports the staged EUDAMED roll-out and extends certain transitional provisions to reduce supply disruption risk.

Value Chain Analysis

The breast imaging value chain runs from upstream component suppliers (flat-panel detectors, X-ray tubes, semiconductors, and specialty materials such as tungsten) to system OEMs for mammography/DBT, ultrasound, MRI, and biopsy guidance. It also includes software and AI developers, distributors and service organizations, and downstream providers such as hospitals, diagnostic imaging centers, and ambulatory settings. Cross-border sourcing is common, with key detector and imaging-component ecosystems in Japan and Europe, while final system integration and commercialization are led by global OEMs and supported by installation, calibration, preventive maintenance, and applications training.

Operational continuity depends on consumables and service readiness as well as capital equipment availability. In interventional workflows, supply constraints can cap procedure volumes, which aligns with the FDA confirmation in June 2026 that breast biopsy needle shortages are anticipated to continue through March 2027, and with Hologic actions in January 2026 involving specific lots of 9-gauge needles for its Brevera Breast Biopsy system. On the capital side, long lead-time electronics and specialized materials can extend production timelines by months, pushing providers toward earlier ordering, multi-sourcing strategies, and software upgrades (AI reconstruction and decision support) that extend the utility of installed bases when hardware delivery timelines tighten.

Market Opportunities and Future Outlook

Workflow-facing AI that can be updated safely and compliantly is a recurring whitespace across modalities, since providers are managing radiologist shortages alongside rising exam volumes. A key enabler is the FDA action effective June 17, 2026 that establishes 21 CFR 892.2055 for radiological machine learning-based quantitative imaging software with predetermined change control plans (Class II, special controls), supporting regulated, iterative model updates without full re-submissions for each change when executed within an approved plan. Recent clearances also indicate demand for software that targets throughput and reporting consistency, including DeepHealth receiving two FDA 510(k) clearances in June 2026 for its Breast Suite to add breast arterial calcification (BAC) and prior exam integration.

Diagnostic pathway expansion is also creating spend pockets in contrast-enhanced and advanced imaging, particularly in centers seeking MRI-like insights with mammography-like access. Siemens Healthineers received FDA 510(k) clearance in June 2026 for contrast-enhanced mammography (CEM) and CEM biopsy features, reflecting movement toward more integrated diagnostic-to-interventional workflows within the mammography suite. Alongside that, national program modernization is opening room for risk stratification and density assessment infrastructure: Cancer Council Australia published the 5-year ROSA Breast Roadmap in April 2026 to transition toward risk-based screening, including work around density assessment pathways and trial design. This points to growing needs for standardized risk tools, automated density measurement, and interoperable data pipelines that connect imaging, reporting, and program governance.